共 47 条
Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus
被引:12
|作者:
Higuchi, Akira
[1
]
Toriniwa, Hiroko
[2
]
Komiya, Tomoyoshi
[2
]
Nakayama, Tetsuo
[3
]
机构:
[1] Kitasato Daiichi Sankyo Vaccine, Div Vaccine Prod, Kitamoto City, Saitama 3640026, Japan
[2] Kitasato Daiichi Sankyo Vaccine, Div Vaccine Dev, Kitamoto City, Saitama 3640026, Japan
[3] Kitasato Inst Life Sci, Lab Viral Infect, Tokyo 1088641, Japan
来源:
关键词:
RANDOMIZED CONTROLLED-TRIAL;
NEUTRALIZING ANTIBODY;
EDMONSTON-ZAGREB;
PHASE-III;
FOLLOW-UP;
MICE;
IMMUNOGENICITY;
PROTECTION;
INFECTION;
RESPONSES;
D O I:
10.1371/journal.pone.0150213
中图分类号:
O [数理科学和化学];
P [天文学、地球科学];
Q [生物科学];
N [自然科学总论];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
An inactivated Japanese encephalitis virus (JEV) vaccine, which induces neutralizing antibodies, has been used for many years in Japan. In the present study, the JEV prM-E protein gene was cloned, inserted at the P/M junction of measles AIK-C cDNA, and an infectious virus was recovered. The JEV E protein was expressed in B95a cells infected with the recombinant virus. Cotton rats were inoculated with recombinant virus. Measles PA antibodies were detected three weeks after immunization. Neutralizing antibodies against JEV developed one week after inoculation, and EIA antibodies were detected three weeks after immunization. The measles AIK-C-based recombinant virus simultaneously induced measles and JEV immune responses, and may be a candidate for infant vaccines. Therefore, the present strategy of recombinant viruses based on a measles vaccine vector would be applicable to the platform for vaccine development.
引用
收藏
页数:9
相关论文